Report cover image

Global Single-target Anti-VEGF Drugs Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 191 Pages
SKU # APRC20282795

Description

Summary

According to APO Research, The global Single-target Anti-VEGF Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Single-target Anti-VEGF Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Single-target Anti-VEGF Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Single-target Anti-VEGF Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Single-target Anti-VEGF Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Single-target Anti-VEGF Drugs include Roche, Chengdu Kanghong Pharmaceutical, Samsung Bioepis, Regeneron Pharmaceuticals, Novartis, Coherus BioSciences and Biocon Biologics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Single-target Anti-VEGF Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Single-target Anti-VEGF Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Single-target Anti-VEGF Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Single-target Anti-VEGF Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Single-target Anti-VEGF Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Single-target Anti-VEGF Drugs sales, projected growth trends, production technology, application and end-user industry.

Single-target Anti-VEGF Drugs Segment by Company

Roche
Chengdu Kanghong Pharmaceutical
Samsung Bioepis
Regeneron Pharmaceuticals
Novartis
Coherus BioSciences
Biocon Biologics
Single-target Anti-VEGF Drugs Segment by Type

Ranibizumab
Conbercept
Faricimab
Brolucizumab
Aflibercept
Other
Single-target Anti-VEGF Drugs Segment by Application

Diabetic Retinopathy
Age-related Macular Degeneration
Other
Single-target Anti-VEGF Drugs Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Single-target Anti-VEGF Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Single-target Anti-VEGF Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Single-target Anti-VEGF Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Single-target Anti-VEGF Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Single-target Anti-VEGF Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Single-target Anti-VEGF Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

191 Pages
1 Market Overview
1.1 Product Definition
1.2 Single-target Anti-VEGF Drugs Market by Type
1.2.1 Global Single-target Anti-VEGF Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Ranibizumab
1.2.3 Conbercept
1.2.4 Faricimab
1.2.5 Brolucizumab
1.2.6 Aflibercept
1.2.7 Other
1.3 Single-target Anti-VEGF Drugs Market by Application
1.3.1 Global Single-target Anti-VEGF Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Diabetic Retinopathy
1.3.3 Age-related Macular Degeneration
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Single-target Anti-VEGF Drugs Market Dynamics
2.1 Single-target Anti-VEGF Drugs Industry Trends
2.2 Single-target Anti-VEGF Drugs Industry Drivers
2.3 Single-target Anti-VEGF Drugs Industry Opportunities and Challenges
2.4 Single-target Anti-VEGF Drugs Industry Restraints
3 Global Market Growth Prospects
3.1 Global Single-target Anti-VEGF Drugs Revenue Estimates and Forecasts (2020-2031)
3.2 Global Single-target Anti-VEGF Drugs Revenue by Region
3.2.1 Global Single-target Anti-VEGF Drugs Revenue by Region: 2020 VS 2024 VS 2031
3.2.2 Global Single-target Anti-VEGF Drugs Revenue by Region (2020-2025)
3.2.3 Global Single-target Anti-VEGF Drugs Revenue by Region (2026-2031)
3.2.4 Global Single-target Anti-VEGF Drugs Revenue Market Share by Region (2020-2031)
3.3 Global Single-target Anti-VEGF Drugs Sales Estimates and Forecasts 2020-2031
3.4 Global Single-target Anti-VEGF Drugs Sales by Region
3.4.1 Global Single-target Anti-VEGF Drugs Sales by Region: 2020 VS 2024 VS 2031
3.4.2 Global Single-target Anti-VEGF Drugs Sales by Region (2020-2025)
3.4.3 Global Single-target Anti-VEGF Drugs Sales by Region (2026-2031)
3.4.4 Global Single-target Anti-VEGF Drugs Sales Market Share by Region (2020-2031)
3.5 US & Canada & Mexico
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
4.1 Global Single-target Anti-VEGF Drugs Revenue by Manufacturers
4.1.1 Global Single-target Anti-VEGF Drugs Revenue by Manufacturers (2020-2025)
4.1.2 Global Single-target Anti-VEGF Drugs Revenue Market Share by Manufacturers (2020-2025)
4.1.3 Global Single-target Anti-VEGF Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2024
4.2 Global Single-target Anti-VEGF Drugs Sales by Manufacturers
4.2.1 Global Single-target Anti-VEGF Drugs Sales by Manufacturers (2020-2025)
4.2.2 Global Single-target Anti-VEGF Drugs Sales Market Share by Manufacturers (2020-2025)
4.2.3 Global Single-target Anti-VEGF Drugs Manufacturers Sales Share Top 10 and Top 5 in 2024
4.3 Global Single-target Anti-VEGF Drugs Sales Price by Manufacturers (2020-2025)
4.4 Global Single-target Anti-VEGF Drugs Key Manufacturers Ranking, 2023 VS 2024 VS 2025
4.5 Global Single-target Anti-VEGF Drugs Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Single-target Anti-VEGF Drugs Manufacturers, Product Type & Application
4.7 Global Single-target Anti-VEGF Drugs Manufacturers' Establishment Date
4.8 Market Competitive Analysis
4.8.1 Global Single-target Anti-VEGF Drugs Market CR5 and HHI
4.8.2 2024 Single-target Anti-VEGF Drugs Tier 1, Tier 2, and Tier 3
5 Single-target Anti-VEGF Drugs Market by Type
5.1 Global Single-target Anti-VEGF Drugs Revenue by Type
5.1.1 Global Single-target Anti-VEGF Drugs Revenue by Type (2020 VS 2024 VS 2031)
5.1.2 Global Single-target Anti-VEGF Drugs Revenue by Type (2020-2031) & (US$ Million)
5.1.3 Global Single-target Anti-VEGF Drugs Revenue Market Share by Type (2020-2031)
5.2 Global Single-target Anti-VEGF Drugs Sales by Type
5.2.1 Global Single-target Anti-VEGF Drugs Sales by Type (2020 VS 2024 VS 2031)
5.2.2 Global Single-target Anti-VEGF Drugs Sales by Type (2020-2031) & (K Units)
5.2.3 Global Single-target Anti-VEGF Drugs Sales Market Share by Type (2020-2031)
5.3 Global Single-target Anti-VEGF Drugs Price by Type
6 Single-target Anti-VEGF Drugs Market by Application
6.1 Global Single-target Anti-VEGF Drugs Revenue by Application
6.1.1 Global Single-target Anti-VEGF Drugs Revenue by Application (2020 VS 2024 VS 2031)
6.1.2 Global Single-target Anti-VEGF Drugs Revenue by Application (2020-2031) & (US$ Million)
6.1.3 Global Single-target Anti-VEGF Drugs Revenue Market Share by Application (2020-2031)
6.2 Global Single-target Anti-VEGF Drugs Sales by Application
6.2.1 Global Single-target Anti-VEGF Drugs Sales by Application (2020 VS 2024 VS 2031)
6.2.2 Global Single-target Anti-VEGF Drugs Sales by Application (2020-2031) & (K Units)
6.2.3 Global Single-target Anti-VEGF Drugs Sales Market Share by Application (2020-2031)
6.3 Global Single-target Anti-VEGF Drugs Price by Application
7 Company Profiles
7.1 Roche
7.1.1 Roche Comapny Information
7.1.2 Roche Business Overview
7.1.3 Roche Single-target Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Roche Single-target Anti-VEGF Drugs Product Portfolio
7.1.5 Roche Recent Developments
7.2 Chengdu Kanghong Pharmaceutical
7.2.1 Chengdu Kanghong Pharmaceutical Comapny Information
7.2.2 Chengdu Kanghong Pharmaceutical Business Overview
7.2.3 Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Product Portfolio
7.2.5 Chengdu Kanghong Pharmaceutical Recent Developments
7.3 Samsung Bioepis
7.3.1 Samsung Bioepis Comapny Information
7.3.2 Samsung Bioepis Business Overview
7.3.3 Samsung Bioepis Single-target Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Samsung Bioepis Single-target Anti-VEGF Drugs Product Portfolio
7.3.5 Samsung Bioepis Recent Developments
7.4 Regeneron Pharmaceuticals
7.4.1 Regeneron Pharmaceuticals Comapny Information
7.4.2 Regeneron Pharmaceuticals Business Overview
7.4.3 Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Product Portfolio
7.4.5 Regeneron Pharmaceuticals Recent Developments
7.5 Novartis
7.5.1 Novartis Comapny Information
7.5.2 Novartis Business Overview
7.5.3 Novartis Single-target Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Novartis Single-target Anti-VEGF Drugs Product Portfolio
7.5.5 Novartis Recent Developments
7.6 Coherus BioSciences
7.6.1 Coherus BioSciences Comapny Information
7.6.2 Coherus BioSciences Business Overview
7.6.3 Coherus BioSciences Single-target Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Coherus BioSciences Single-target Anti-VEGF Drugs Product Portfolio
7.6.5 Coherus BioSciences Recent Developments
7.7 Biocon Biologics
7.7.1 Biocon Biologics Comapny Information
7.7.2 Biocon Biologics Business Overview
7.7.3 Biocon Biologics Single-target Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Biocon Biologics Single-target Anti-VEGF Drugs Product Portfolio
7.7.5 Biocon Biologics Recent Developments
8 North America
8.1 North America Single-target Anti-VEGF Drugs Market Size by Type
8.1.1 North America Single-target Anti-VEGF Drugs Revenue by Type (2020-2031)
8.1.2 North America Single-target Anti-VEGF Drugs Sales by Type (2020-2031)
8.1.3 North America Single-target Anti-VEGF Drugs Price by Type (2020-2031)
8.2 North America Single-target Anti-VEGF Drugs Market Size by Application
8.2.1 North America Single-target Anti-VEGF Drugs Revenue by Application (2020-2031)
8.2.2 North America Single-target Anti-VEGF Drugs Sales by Application (2020-2031)
8.2.3 North America Single-target Anti-VEGF Drugs Price by Application (2020-2031)
8.3 North America Single-target Anti-VEGF Drugs Market Size by Country
8.3.1 North America Single-target Anti-VEGF Drugs Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
8.3.2 North America Single-target Anti-VEGF Drugs Sales by Country (2020 VS 2024 VS 2031)
8.3.3 North America Single-target Anti-VEGF Drugs Price by Country (2020-2031)
8.3.4 United States
8.3.5 Canada
8.3.6 Mexico
9 Europe
9.1 Europe Single-target Anti-VEGF Drugs Market Size by Type
9.1.1 Europe Single-target Anti-VEGF Drugs Revenue by Type (2020-2031)
9.1.2 Europe Single-target Anti-VEGF Drugs Sales by Type (2020-2031)
9.1.3 Europe Single-target Anti-VEGF Drugs Price by Type (2020-2031)
9.2 Europe Single-target Anti-VEGF Drugs Market Size by Application
9.2.1 Europe Single-target Anti-VEGF Drugs Revenue by Application (2020-2031)
9.2.2 Europe Single-target Anti-VEGF Drugs Sales by Application (2020-2031)
9.2.3 Europe Single-target Anti-VEGF Drugs Price by Application (2020-2031)
9.3 Europe Single-target Anti-VEGF Drugs Market Size by Country
9.3.1 Europe Single-target Anti-VEGF Drugs Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
9.3.2 Europe Single-target Anti-VEGF Drugs Sales by Country (2020 VS 2024 VS 2031)
9.3.3 Europe Single-target Anti-VEGF Drugs Price by Country (2020-2031)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Russia
9.3.9 Spain
9.3.10 Netherlands
10 China
10.1 China Single-target Anti-VEGF Drugs Market Size by Type
10.1.1 China Single-target Anti-VEGF Drugs Revenue by Type (2020-2031)
10.1.2 China Single-target Anti-VEGF Drugs Sales by Type (2020-2031)
10.1.3 China Single-target Anti-VEGF Drugs Price by Type (2020-2031)
10.2 China Single-target Anti-VEGF Drugs Market Size by Application
10.2.1 China Single-target Anti-VEGF Drugs Revenue by Application (2020-2031)
10.2.2 China Single-target Anti-VEGF Drugs Sales by Application (2020-2031)
10.2.3 China Single-target Anti-VEGF Drugs Price by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Single-target Anti-VEGF Drugs Market Size by Type
11.1.1 Asia Single-target Anti-VEGF Drugs Revenue by Type (2020-2031)
11.1.2 Asia Single-target Anti-VEGF Drugs Sales by Type (2020-2031)
11.1.3 Asia Single-target Anti-VEGF Drugs Price by Type (2020-2031)
11.2 Asia Single-target Anti-VEGF Drugs Market Size by Application
11.2.1 Asia Single-target Anti-VEGF Drugs Revenue by Application (2020-2031)
11.2.2 Asia Single-target Anti-VEGF Drugs Sales by Application (2020-2031)
11.2.3 Asia Single-target Anti-VEGF Drugs Price by Application (2020-2031)
11.3 Asia Single-target Anti-VEGF Drugs Market Size by Country
11.3.1 Asia Single-target Anti-VEGF Drugs Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
11.3.2 Asia Single-target Anti-VEGF Drugs Sales by Country (2020 VS 2024 VS 2031)
11.3.3 Asia Single-target Anti-VEGF Drugs Price by Country (2020-2031)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 Taiwan
11.3.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Single-target Anti-VEGF Drugs Market Size by Type
12.1.1 SAMEA Single-target Anti-VEGF Drugs Revenue by Type (2020-2031)
12.1.2 SAMEA Single-target Anti-VEGF Drugs Sales by Type (2020-2031)
12.1.3 SAMEA Single-target Anti-VEGF Drugs Price by Type (2020-2031)
12.2 SAMEA Single-target Anti-VEGF Drugs Market Size by Application
12.2.1 SAMEA Single-target Anti-VEGF Drugs Revenue by Application (2020-2031)
12.2.2 SAMEA Single-target Anti-VEGF Drugs Sales by Application (2020-2031)
12.2.3 SAMEA Single-target Anti-VEGF Drugs Price by Application (2020-2031)
12.3 SAMEA Single-target Anti-VEGF Drugs Market Size by Country
12.3.1 SAMEA Single-target Anti-VEGF Drugs Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
12.3.2 SAMEA Single-target Anti-VEGF Drugs Sales by Country (2020 VS 2024 VS 2031)
12.3.3 SAMEA Single-target Anti-VEGF Drugs Price by Country (2020-2031)
12.3.4 Brazil
12.3.5 Argentina
12.3.6 Chile
12.3.7 Colombia
12.3.8 Peru
12.3.9 Saudi Arabia
12.3.10 Israel
12.3.11 UAE
12.3.12 Turkey
12.3.13 Iran
12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
13.1 Single-target Anti-VEGF Drugs Value Chain Analysis
13.1.1 Single-target Anti-VEGF Drugs Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Single-target Anti-VEGF Drugs Production Mode & Process
13.2 Single-target Anti-VEGF Drugs Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Single-target Anti-VEGF Drugs Distributors
13.2.3 Single-target Anti-VEGF Drugs Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.